Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe)
Open Access
- 16 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 18 (1), 1-8
- https://doi.org/10.1186/s12916-020-01606-w
Abstract
PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential treatment benefit on overall survival. In this study, we externally validated the model in a large independent dataset and compared performance to existing models and within treatment groups. Men with non-metastatic prostate cancer and prostate-specific antigen (PSA) < 100 ng/ml diagnosed between 2000 and 2010 in the nationwide population-based Prostate Cancer data Base Sweden (PCBaSe) were included. Data on age, PSA, clinical stage, grade group, biopsy involvement, primary treatment and comorbidity were retrieved. Sixty-nine thousand two hundred six men were included with 13.9 years of median follow-up. Fifteen-year survival estimates were calculated using PREDICT Prostate for prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM). Discrimination was assessed using Harrell’s concordance (c)-index in R. Calibration was evaluated using cumulative available follow-up in Stata (TX, USA). Overall discrimination of PREDICT Prostate was good with c-indices of 0.85 (95% CI 0.85–0.86) for PCSM and 0.79 (95% CI 0.79–0.80) for ACM. Overall calibration of the model was excellent with 25,925 deaths predicted and 25,849 deaths observed. Within the conservative management and radical treatment groups, c-indices for 15-year PCSM were 0.81 and 0.78, respectively. Calibration also remained good within treatment groups. The discrimination of PREDICT Prostate significantly outperformed the EAU, NCCN and CAPRA scores for both PCSM and ACM within this cohort overall. A key limitation is the use of retrospective cohort data. This large external validation demonstrates that PREDICT Prostate is a robust and generalisable model to aid clinical decision-making.Funding Information
- The Urology Foundation (Research Scholarship)
This publication has 27 references indexed in Scilit:
- Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancerProstate Cancer and Prostatic Diseases, 2014
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013European Urology, 2013
- Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0International Journal of Epidemiology, 2012
- Inaccuracies in assignment of clinical stage for localized prostate cancerCancer, 2010
- Patient Decision Aids for Prostate Cancer Treatment: A Systematic Review of the LiteratureCA: A Cancer Journal for Clinicians, 2009
- THE UCSF CANCER OF THE PROSTATE RISK ASSESSMENT (CAPRA) SCORE ACCURATELY PREDICTS METASTASIS, PROSTATE CANCER MORTALITY, AND ALL-CAUSE MORTALITY REGARDLESS OF TREATMENT TYPEJournal of Urology, 2008
- Reliability of death certificates in prostate cancer patientsScandinavian Journal of Urology and Nephrology, 2008
- THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMYJournal of Urology, 2005
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998